Medicinsk Lustgas Air Liquide (Nitrous Oxide): Uses, Dosage & Side Effects
A medical-grade inhalation anaesthetic and analgesic gas used for procedural sedation, labour pain, and short-term pain relief
Medicinsk Lustgas Air Liquide is a pharmaceutical-grade nitrous oxide (N2O) supplied as a compressed medicinal gas. Commonly known as “laughing gas,” nitrous oxide has been used in medical practice for over 175 years, making it one of the oldest anaesthetic agents still in clinical use. It provides rapid-onset analgesia and mild anxiolysis when inhaled, typically as a 50:50 mixture with oxygen. It is widely used for labour pain, procedural sedation in emergency departments, dental procedures, wound care, and paediatric pain management. Its key clinical advantages are extremely fast onset (2–5 minutes), rapid offset upon cessation, and an excellent safety profile when administered correctly with adequate oxygen supplementation.
Quick Facts: Medical Nitrous Oxide
Key Takeaways
- Nitrous oxide provides rapid, reversible analgesia: Effects begin within 2–5 minutes of inhalation and dissipate within 5 minutes of stopping, making it ideal for short procedures and labour pain management.
- Must always be administered with at least 21% oxygen: Pure nitrous oxide without adequate oxygen supplementation can cause hypoxia. Clinical delivery systems are designed with fail-safe mechanisms to prevent hypoxic mixtures.
- Not suitable for patients with trapped gas: Nitrous oxide diffuses into air-filled body cavities and can expand trapped gas, making it contraindicated in pneumothorax, bowel obstruction, and middle ear conditions.
- Prolonged exposure inactivates vitamin B12: Repeated or extended use can irreversibly oxidise vitamin B12, potentially causing megaloblastic anaemia and neurological damage. Standard short-term procedural use carries minimal risk.
- Self-administered demand-valve systems enhance safety: When patients control their own inhalation via a demand valve, the built-in safety mechanism ensures the mask falls away if sedation becomes excessive, automatically stopping gas delivery.
What Is Medicinsk Lustgas Air Liquide and What Is It Used For?
Medicinsk Lustgas Air Liquide is a pharmaceutical-grade nitrous oxide (N2O) used as an inhalation analgesic and mild sedative. It is administered as a gas mixture with oxygen to provide rapid pain relief during medical and dental procedures, labour, emergency care, and paediatric treatments.
Nitrous oxide, commonly referred to as “laughing gas,” is a colourless, odourless to slightly sweet-smelling gas that has been a cornerstone of clinical analgesia and anaesthesia since the mid-19th century. Sir Humphry Davy first described its analgesic properties in 1800, and it was introduced into dental practice by Horace Wells in 1844. Today, it remains one of the most widely used analgesic gases in the world, valued for its rapid onset, predictable effects, and excellent safety profile.
Medicinsk Lustgas Air Liquide is supplied as 100% nitrous oxide in compressed gas cylinders. Before reaching the patient, it is always mixed with oxygen – most commonly in a 50:50 ratio (equimolar mixture) through premixed cylinders (such as Entonox or Livopan) or via dedicated blending delivery systems that allow the concentration to be adjusted by the clinician. The product complies with the European Pharmacopoeia monograph for medicinal nitrous oxide and is manufactured under strict pharmaceutical Good Manufacturing Practice (GMP) standards.
Unlike general anaesthetic agents that produce unconsciousness, nitrous oxide at standard analgesic concentrations (30–70%) produces a state of conscious sedation characterised by reduced pain perception, mild euphoria, decreased anxiety, and maintained airway reflexes. The patient remains awake and cooperative, able to follow verbal commands and breathe independently throughout the procedure. This makes it fundamentally different from deep sedation or general anaesthesia.
Clinical Indications
Medical nitrous oxide is approved and widely used for the following indications:
- Labour and delivery pain: One of the most common uses worldwide, providing effective analgesia during contractions. The labouring woman self-administers the gas through a demand-valve mouthpiece, inhaling at the onset of each contraction
- Procedural sedation and analgesia: Used in emergency departments and outpatient clinics for painful procedures such as fracture reduction, joint dislocation relocation, abscess drainage, and wound suturing
- Dental procedures: Widely used in dental practice for anxious patients, particularly children, during fillings, extractions, and other dental treatments
- Paediatric pain management: Particularly valuable in children due to its non-invasive route of administration, rapid onset, and child-friendly delivery via flavoured masks
- Wound care and dressing changes: Used in burn units and wound care clinics for analgesia during painful dressing changes and wound debridement
- Pre-hospital emergency care: Administered by paramedics and emergency medical technicians for acute trauma pain, fractures, and cardiac chest pain (provided no contraindications exist)
- Diagnostic procedures: Used during colonoscopy, lumbar puncture, bone marrow biopsy, and other mildly to moderately painful diagnostic investigations
How Nitrous Oxide Works
The analgesic and anxiolytic effects of nitrous oxide result from multiple pharmacological mechanisms acting simultaneously on the central nervous system. Unlike most other anaesthetic agents that operate through a single receptor system, nitrous oxide modulates several neuronal pathways:
NMDA receptor antagonism: Nitrous oxide inhibits N-methyl-D-aspartate (NMDA) glutamate receptors in the brain and spinal cord. NMDA receptors play a central role in pain signalling and central sensitisation. By blocking these receptors, nitrous oxide reduces the transmission and perception of pain signals, similar to the mechanism of ketamine but with considerably less potency.
Opioidergic pathway activation: Nitrous oxide stimulates the release of endogenous opioid peptides (endorphins and enkephalins) from the periaqueductal grey matter and other brainstem nuclei. These endogenous opioids activate descending pain-inhibitory pathways, contributing significantly to the analgesic effect. This mechanism explains why opioid receptor antagonists such as naloxone can partially reverse nitrous oxide analgesia in experimental settings.
GABAergic modulation: At higher concentrations, nitrous oxide enhances the activity of gamma-aminobutyric acid type A (GABAA) receptors, contributing to its anxiolytic and mild sedative properties. This mechanism is shared with benzodiazepines and barbiturates, though nitrous oxide acts at a distinct binding site.
Noradrenergic descending inhibition: Nitrous oxide activates noradrenergic neurons in the brainstem (particularly the locus coeruleus), which project to the spinal dorsal horn and inhibit nociceptive (pain) signal transmission. This descending inhibitory pathway provides an additional layer of analgesia independent of the opioid system.
The remarkably fast onset and recovery from nitrous oxide is due to its very low blood:gas partition coefficient (0.47). This means that nitrous oxide transfers rapidly from the lungs into the blood and equally rapidly from the blood back into the lungs for exhalation. The brain reaches effective analgesic concentrations within 2–5 minutes of inhalation, and the gas is almost entirely eliminated within 3–5 minutes of breathing room air. Nitrous oxide undergoes virtually no metabolism in the body – over 99.9% is eliminated unchanged through the lungs.
What Should You Know Before Receiving Nitrous Oxide?
Nitrous oxide is contraindicated in conditions where gas may become trapped in body cavities, including pneumothorax, bowel obstruction, and after recent middle ear surgery. It should be used with caution in patients with vitamin B12 deficiency, severe respiratory conditions, and during the first trimester of pregnancy.
Although nitrous oxide has an excellent safety profile when used correctly, there are several important contraindications and precautions that must be considered before administration. These relate primarily to the physical property of nitrous oxide to diffuse into and expand air-filled spaces, and its biochemical effect on vitamin B12 metabolism.
Contraindications – Do Not Use Nitrous Oxide If You Have:
- Pneumothorax (collapsed lung): Nitrous oxide diffuses into the pleural space faster than nitrogen diffuses out, causing rapid expansion of the pneumothorax and potentially fatal tension pneumothorax
- Bowel obstruction or distended bowel: Gas expansion in obstructed bowel loops can cause perforation, peritonitis, and life-threatening complications
- Recent middle ear surgery or middle ear grafting: Expansion of gas in the middle ear cavity can displace tympanic membrane grafts and cause surgical failure
- Severe bullous emphysema: Expansion of gas within pulmonary bullae can cause rupture and pneumothorax
- Decompression sickness (the bends): Nitrous oxide can expand nitrogen bubbles in tissues, worsening decompression illness
- Intracranial air or pneumocephalus: Following neurosurgery, head trauma, or lumbar puncture where intracranial air may be present, nitrous oxide expansion can cause raised intracranial pressure
- Maxillofacial injuries with suspected air entrapment: Risk of gas expansion in tissue planes around the orbits or in the sinuses
- Impaired level of consciousness: Patients who cannot maintain protective airway reflexes should not receive nitrous oxide sedation without full anaesthetic monitoring
Warnings and Precautions
Discuss the following conditions with your healthcare provider before receiving nitrous oxide, as additional precautions or monitoring may be required:
- Vitamin B12 deficiency or pernicious anaemia: Nitrous oxide irreversibly oxidises the cobalt ion in vitamin B12 (cobalamin), rendering it inactive. In patients with pre-existing B12 deficiency, even a single exposure can precipitate acute neurological deterioration including subacute combined degeneration of the spinal cord
- Current methotrexate treatment: Nitrous oxide may enhance the antifolate effects of methotrexate, increasing the risk of bone marrow suppression and pancytopenia. Avoid concurrent use
- Severe chronic obstructive pulmonary disease (COPD): Patients with severe lung disease may have impaired gas exchange affecting the onset and offset of nitrous oxide. Close monitoring is required
- Significantly raised intracranial pressure: Though the clinical significance is debated, nitrous oxide may theoretically increase cerebral blood flow. Exercise caution in patients with space-occupying lesions or acute head injury
- Cardiovascular instability: Nitrous oxide has mild myocardial depressant effects and may be inappropriate in haemodynamically unstable patients
- Severe anaemia: Reduced oxygen-carrying capacity combined with the dilutional effect of nitrous oxide on inspired oxygen may compromise tissue oxygenation
When nitrous oxide administration is stopped, large volumes of the gas rapidly diffuse from the blood back into the alveoli, diluting the alveolar oxygen concentration. This phenomenon, known as diffusion hypoxia (or the Fink effect), can cause temporary oxygen desaturation. To prevent this, patients should always breathe supplemental 100% oxygen for at least 3–5 minutes after discontinuation of nitrous oxide. Pulse oximetry monitoring should continue until oxygen saturation has returned to baseline.
Pregnancy and Breastfeeding
Labour and delivery: Nitrous oxide (typically 50% N2O in 50% O2) is one of the most widely used analgesic options during labour and has an extensive safety record spanning many decades. Short-term use during active labour is not associated with adverse neonatal outcomes in large observational studies and meta-analyses. It does not inhibit uterine contractions and does not require intravenous access, making it a convenient first-line analgesic option. The self-administration model provides an inherent safety margin.
Early pregnancy: Nitrous oxide should be avoided during the first trimester unless the clinical benefit clearly outweighs the potential risk. Animal studies have demonstrated teratogenic effects at very high concentrations with prolonged exposure, and there is a theoretical concern that B12 inactivation could affect folate-dependent DNA synthesis during organogenesis. However, the clinical evidence from inadvertent early pregnancy exposures during procedures has not demonstrated a clear increase in birth defects.
Breastfeeding: Due to its extremely rapid pulmonary elimination (virtually complete within 5 minutes of cessation), nitrous oxide does not accumulate in breast milk in clinically significant concentrations. Breastfeeding can be safely resumed immediately after a procedure involving nitrous oxide.
Healthcare workers regularly exposed to ambient nitrous oxide (particularly in delivery suites and dental surgeries) should be aware of potential reproductive risks. Chronic occupational exposure has been associated with reduced fertility and increased spontaneous abortion rates in some epidemiological studies, although the evidence is not entirely consistent. Adequate scavenging systems and room ventilation are essential. Occupational exposure limits vary by jurisdiction but are typically set at 25–100 ppm time-weighted average (TWA) over 8 hours.
How Does Nitrous Oxide Interact with Other Drugs?
Nitrous oxide enhances the sedative effects of other CNS depressants including opioids, benzodiazepines, and general anaesthetics. It can potentiate the antifolate effects of methotrexate. The interaction profile is generally favourable, but additive sedation must be monitored when combining with other sedative agents.
As an inhalation analgesic with multiple mechanisms of action (NMDA antagonism, opioidergic stimulation, GABAergic enhancement), nitrous oxide has the potential to interact pharmacodynamically with various drug classes. The most clinically relevant interactions involve additive or synergistic central nervous system depression and enhancement of antifolate toxicity.
Major Interactions (Clinically Significant)
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Methotrexate | Nitrous oxide inactivates vitamin B12, which impairs methionine synthase – the same folate-dependent enzyme inhibited by methotrexate. Combined effect increases risk of severe pancytopenia | Avoid concurrent use; risk of life-threatening bone marrow suppression |
| Opioid analgesics (morphine, fentanyl) | Additive analgesia and respiratory depression; nitrous oxide potentiates opioid-mediated sedation through shared endorphin pathways | Reduce opioid doses when co-administered; monitor respiratory rate and SpO2 |
| Benzodiazepines (midazolam, diazepam) | Enhanced sedation through additive GABAergic effects; increased risk of excessive sedation and airway compromise | Reduce benzodiazepine doses; ensure continuous clinical monitoring |
| Other general anaesthetics (sevoflurane, propofol) | Nitrous oxide reduces the minimum alveolar concentration (MAC) of volatile anaesthetics by approximately 0.5 MAC per 1% inspired N2O, and reduces propofol induction doses | Intentionally used to reduce anaesthetic doses; requires adjusted dosing protocols |
| Bleomycin | Nitrous oxide increases the fraction of inspired oxygen (FiO2) administered during anaesthesia, which can potentiate bleomycin-induced pulmonary toxicity | Use with caution in patients receiving or who have recently received bleomycin chemotherapy |
Other Important Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Antifolate drugs (trimethoprim, pyrimethamine) | Additive folate antagonism through vitamin B12 inactivation combined with direct dihydrofolate reductase inhibition | Monitor full blood count; consider B12/folate supplementation with prolonged N2O exposure |
| CNS depressants (alcohol, antihistamines) | Additive central nervous system depression; enhanced sedation, dizziness, and impaired coordination | Avoid alcohol before and after procedures; monitor sedation levels |
| Muscle relaxants | Mild potentiation of neuromuscular blockade when used within general anaesthesia | Routine monitoring with nerve stimulator during anaesthesia |
The interaction between nitrous oxide and vitamin B12 is a chemical reaction, not a receptor-mediated drug interaction. Nitrous oxide irreversibly oxidises the cobalt atom in cobalamin from the Co(I) to the Co(III) state, rendering vitamin B12 non-functional as a cofactor for methionine synthase. This enzyme is essential for converting homocysteine to methionine and for regenerating tetrahydrofolate, which is required for DNA synthesis. The clinical consequences (megaloblastic anaemia, neuropathy) typically require prolonged or repeated exposure, but patients with pre-existing B12 deficiency can develop symptoms after even brief exposure.
What Is the Correct Dosage of Nitrous Oxide?
Nitrous oxide is typically administered as a 50:50 mixture with oxygen for self-administered analgesia, or at variable concentrations (30–70% N2O in oxygen) through dedicated delivery systems. The concentration and duration are determined by the clinical situation and the patient’s response, always under medical supervision.
Unlike oral medications with fixed dose tablets, nitrous oxide is a gas administered continuously via inhalation. The “dose” is determined by the concentration of nitrous oxide in the inspired gas mixture and the duration of administration. The clinician adjusts these parameters in real time based on the patient’s pain level, level of consciousness, oxygen saturation, and the clinical context of the procedure.
Adults
Self-Administered Analgesia (Demand Valve System)
Concentration: 50% nitrous oxide / 50% oxygen (premixed, equimolar)
Method: Patient holds a demand-valve mouthpiece or face mask and inhales on demand. The gas is only delivered when the patient actively inspires through the device.
Onset: Begin inhalation 2–3 minutes before the anticipated painful stimulus. Effective analgesia is typically achieved within 3–5 deep breaths.
Duration: Continue throughout the procedure as needed. There is no strict maximum duration for a single session, but exposure beyond 6 hours should generally be avoided without B12 monitoring.
Recovery: Administer 100% oxygen for 3–5 minutes post-procedure to prevent diffusion hypoxia.
Clinician-Controlled Variable Concentration
Concentration: 30–70% nitrous oxide in oxygen, titrated to patient response
Method: Delivered via a calibrated anaesthetic machine or dedicated N2O/O2 blender through a nasal hood or face mask with continuous flow.
Monitoring: Continuous pulse oximetry, clinical observation of sedation level, and verbal contact maintained throughout.
Maximum concentration: 70% N2O / 30% O2 is the maximum recommended concentration to ensure adequate oxygenation. Modern delivery systems have built-in fail-safe mechanisms that prevent delivery of less than 21–30% oxygen.
Children
Paediatric Procedural Sedation
Concentration: 50% N2O / 50% O2 (premixed) or 30–50% via a blender system, depending on the child’s age and the procedure
Minimum age: Generally used from age 3–4 years and upwards, as younger children may not cooperate with the mask or mouthpiece. Some centres use it from age 1 year with an appropriately sized face mask under close supervision.
Method: Child-friendly masks (often with flavoured scents) are used. For self-administration, the child must be old enough to hold the mouthpiece and follow instructions.
Duration: Keep as short as clinically necessary. Paediatric sessions typically last 10–30 minutes.
Special considerations: Ensure the child has fasted according to institutional protocols if deep sedation is a possibility. Monitor with pulse oximetry throughout.
Elderly Patients
Geriatric Dosing
Concentration: Start with lower concentrations (30–50% N2O) and titrate upward cautiously
Considerations: Elderly patients may be more sensitive to the sedative effects of nitrous oxide due to age-related changes in brain receptor density and concurrent medications. They are also at higher risk of vitamin B12 deficiency.
Monitoring: Enhanced monitoring recommended, including continuous pulse oximetry and clinical assessment of sedation depth. Ensure adequate post-procedure recovery with supplemental oxygen.
Important Dosing Principles
- Titration to effect: Always start at a lower concentration and increase gradually based on the patient’s response. This minimises the risk of over-sedation while achieving adequate analgesia
- Maintain verbal contact: The target is conscious sedation, not deep sedation. If the patient stops responding to verbal commands, reduce the nitrous oxide concentration immediately
- Oxygen safety margin: Never deliver less than 21% oxygen (and preferably not less than 30%). Modern delivery equipment has engineering controls to prevent hypoxic mixtures
- Post-procedure oxygen: Always provide 100% oxygen (or high-flow air) for 3–5 minutes after stopping nitrous oxide to prevent diffusion hypoxia
- Scavenging: Use active scavenging systems to minimise occupational exposure of healthcare staff to waste anaesthetic gas
Overdose
True overdose with nitrous oxide is rare when modern delivery equipment with fail-safe mechanisms is used. However, excessive concentrations or inadvertent delivery of a hypoxic mixture can occur through equipment failure or human error.
Signs of excessive sedation: Loss of verbal contact, deep sedation, loss of protective airway reflexes, respiratory depression, cyanosis, nausea and vomiting. In extreme cases, delivery of a hypoxic gas mixture can cause loss of consciousness, brain damage, and death.
Management of overexposure: Immediately discontinue nitrous oxide delivery. Administer 100% oxygen by face mask. Ensure airway patency (head tilt, chin lift, or jaw thrust). Provide assisted ventilation if necessary. Monitor with continuous pulse oximetry. In the self-administered demand-valve system, overexposure is inherently limited because the sedated patient loses the ability to hold the mouthpiece, automatically stopping gas delivery.
What Are the Side Effects of Nitrous Oxide?
The most common side effects of nitrous oxide are nausea, vomiting, dizziness, and euphoria. These are usually mild and resolve within minutes of stopping inhalation. Serious side effects, including vitamin B12 inactivation and neurological damage, are associated with prolonged or repeated exposure rather than standard short-term procedural use.
Nitrous oxide is generally well tolerated when used at standard analgesic concentrations for short-duration procedures. The side effect profile is favourable compared to systemic opioids and sedatives, largely because the gas is rapidly eliminated without metabolism. However, healthcare professionals and patients should be aware of both the common transient effects and the rare but serious consequences of prolonged exposure.
Very Common (affects more than 1 in 10 patients)
Frequency: >10%
- Dizziness and lightheadedness
- Euphoria (“floating” sensation)
- Tingling or numbness in extremities (paraesthesia)
- Altered perception of sounds and surroundings
Common (affects 1 in 10 to 1 in 100 patients)
Frequency: 1–10%
- Nausea
- Vomiting (especially at concentrations above 50%)
- Headache (usually mild, resolves within hours)
- Drowsiness and fatigue
- Excessive sweating
Uncommon (affects 1 in 100 to 1 in 1,000 patients)
Frequency: 0.1–1%
- Anxiety, restlessness, or agitation (paradoxical reaction)
- Ear discomfort or pressure (due to gas expansion in middle ear)
- Abdominal distension
- Transient oxygen desaturation (diffusion hypoxia if post-procedure O2 not given)
Rare (affects fewer than 1 in 1,000 patients)
Frequency: <0.1%
- Megaloblastic anaemia (with prolonged/repeated exposure – due to B12 inactivation)
- Subacute combined degeneration of the spinal cord (with chronic exposure)
- Peripheral neuropathy (numbness, weakness in hands and feet)
- Bone marrow suppression (agranulocytosis, pancytopenia)
- Pneumothorax aggravation (if used despite contraindication)
Nausea and Vomiting
Nausea is the most troublesome common side effect, reported in approximately 5–15% of patients depending on the concentration used and the duration of exposure. It is more frequent at concentrations above 50% and when nitrous oxide is combined with opioid analgesics. Vomiting is less common but can occur, particularly if the patient has recently eaten. To minimise the risk, patients should ideally avoid heavy meals for 2 hours before a planned procedure, and an anti-emetic can be considered for patients with a history of nausea.
Neurological Effects of Prolonged Exposure
The most clinically serious adverse effect of nitrous oxide is its ability to inactivate vitamin B12 through irreversible oxidation. This is a dose-dependent and time-dependent effect that becomes clinically relevant with prolonged (more than 6–12 hours continuous) or repeated exposure (daily or multiple times weekly). The neurological consequences include:
- Subacute combined degeneration of the spinal cord: Progressive demyelination of the dorsal columns and lateral corticospinal tracts, causing sensory ataxia, weakness, and loss of proprioception. This is the most feared neurological complication
- Peripheral neuropathy: Symmetrical numbness and tingling in hands and feet, progressing to weakness if exposure continues
- Megaloblastic anaemia: Due to impaired DNA synthesis from folate cycle disruption. Characterised by large immature red blood cells, fatigue, and pallor
- Cognitive changes: Memory impairment, confusion, and psychomotor retardation with chronic exposure
Contact your healthcare provider urgently if you develop persistent numbness or tingling in your hands or feet, unsteadiness when walking, unusual fatigue or pallor, or cognitive difficulties following nitrous oxide exposure. These symptoms may indicate B12 deficiency-related neurological damage, which is potentially reversible if treated promptly with B12 supplementation but can become permanent if untreated.
How Should Nitrous Oxide Be Stored?
Nitrous oxide cylinders must be stored upright in well-ventilated areas, away from heat sources and flammable materials, at temperatures between −20°C and +50°C. Cylinders should be secured to prevent falling and must comply with local regulations for compressed medical gas storage.
As a compressed medicinal gas, nitrous oxide has specific storage requirements that differ significantly from conventional medications. Improper storage can lead to safety hazards, equipment malfunction, or degradation of gas quality. The following guidelines are based on international pharmacopoeial standards and compressed gas safety regulations.
Storage Conditions
- Temperature: Store at temperatures between −20°C and +50°C. Avoid exposure to extreme heat or direct flame, which can cause dangerous pressure increases in the cylinder. For premixed N2O/O2 cylinders (Entonox), storage below −6°C can cause the gases to separate (Poynting effect), delivering a hypoxic mixture. These cylinders should be stored horizontally at temperatures above +10°C for at least 24 hours before use, or inverted three times to remix the gases
- Ventilation: Store in well-ventilated areas. Nitrous oxide is denser than air (relative density 1.5) and can accumulate at floor level in enclosed spaces, creating an oxygen-depleted atmosphere
- Position: Store cylinders upright and secured with chains, straps, or in designated cylinder racks to prevent toppling. Nitrous oxide is stored as a liquefied gas under pressure; cylinders must not be laid on their sides during use (though this is acceptable for storage of premixed cylinders)
- Separation: Keep away from flammable gases, oils, greases, and other combustible materials. Although nitrous oxide itself is not flammable, it is a strong oxidising agent that vigorously supports combustion
- Identification: Cylinders are colour-coded according to international standards (blue body in the EU/international system). Never use a cylinder with damaged or missing labels
Safety Precautions
- Never apply oil or grease to cylinder valves, regulators, or fittings – nitrous oxide supports combustion and can cause fire or explosion on contact with hydrocarbons
- Always use the correct pressure regulator designed for nitrous oxide – pin-index safety systems prevent incorrect cylinder-to-regulator connections
- Close cylinder valves completely when not in use
- Return empty cylinders to the supplier; do not dispose of in general waste
- Check cylinder integrity and valve condition regularly. Do not use damaged cylinders
What Does Medicinsk Lustgas Air Liquide Contain?
Medicinsk Lustgas Air Liquide contains a single active ingredient: nitrous oxide (dinitrogen monoxide, N2O) at 100% volume per volume (v/v). It is a pure medicinal gas with no excipients, solvents, or additives.
Unlike tablet or liquid pharmaceutical formulations that contain multiple excipients (binders, fillers, coatings, preservatives), medicinal nitrous oxide is a single-component product. The gas itself is the active pharmaceutical ingredient, supplied in its pure form.
Active Ingredient
- Nitrous oxide (dinitrogen monoxide, N2O): 100% v/v, complying with the European Pharmacopoeia monograph for Medicinal Nitrous Oxide (Ph. Eur.)
Physical and Chemical Properties
| Property | Value |
|---|---|
| Chemical formula | N2O (dinitrogen monoxide) |
| Molecular weight | 44.01 g/mol |
| Appearance | Colourless gas |
| Odour | Slightly sweet |
| Boiling point | −88.5°C at 1 atm |
| Cylinder pressure | ~44 bar at 15°C (liquefied gas) |
| Relative density (gas) | 1.53 (heavier than air) |
| Blood:gas partition coefficient | 0.47 (low solubility = rapid onset/offset) |
| Supports combustion | Yes (strong oxidiser) – not itself flammable |
Packaging
Medicinsk Lustgas Air Liquide is supplied in steel or aluminium gas cylinders in various sizes, from small portable cylinders for ambulance use to large manifold-connected cylinders for hospital piped gas systems. Cylinder body colour for nitrous oxide is blue (EU standard). Each cylinder is fitted with a pressure-reducing valve and a pin-index safety system (PISS) or bull-nose connector specific to nitrous oxide, preventing accidental connection to the wrong gas supply.
The product is manufactured and distributed by Air Liquide, one of the world’s leading medical gas suppliers, in compliance with EU GMP standards for medicinal gases and the European Pharmacopoeia requirements for purity (minimum 98.0% N2O), moisture content, and absence of contaminants including carbon monoxide, carbon dioxide, nitrogen dioxide, and sulphur dioxide.
Frequently Asked Questions About Nitrous Oxide
Medical nitrous oxide (N2O) is used for short-term pain relief and mild sedation during medical and dental procedures. Common uses include labour pain management, wound dressing changes, minor surgical procedures, dental treatments, emergency fracture management, and paediatric procedural sedation. It is typically administered as a 50:50 mixture with oxygen and provides rapid onset of analgesia within 2–5 minutes.
Nitrous oxide (50% in oxygen) is widely used and considered safe for labour pain relief, with decades of clinical experience and safety data. Short-term use during active labour is not associated with adverse neonatal outcomes. However, prolonged or repeated exposure during early pregnancy should be avoided due to the theoretical risk of vitamin B12 inactivation affecting fetal development. Always inform your healthcare provider if you are or might be pregnant.
Nitrous oxide has one of the fastest onsets and offsets of any analgesic agent. Due to its very low blood-gas solubility, effective analgesia is reached within 2–5 minutes of inhalation. Upon stopping, the gas is eliminated through the lungs and patients return to baseline within approximately 5 minutes. This rapid recovery means most patients can resume normal activities, including driving, shortly after the procedure – though your healthcare provider will confirm when it is safe.
Standard short-term medical use of nitrous oxide carries minimal risk of neurological damage. However, prolonged or repeated exposure can inactivate vitamin B12, which is essential for nerve health (myelin synthesis). Chronic exposure can lead to peripheral neuropathy and spinal cord degeneration. This is primarily a concern with recreational misuse or chronic occupational exposure, not with occasional medical use. Patients with pre-existing B12 deficiency are at higher risk and should inform their healthcare provider before receiving nitrous oxide.
Nitrous oxide should not be used in patients with pneumothorax (collapsed lung), bowel obstruction, recent middle ear surgery, severe bullous emphysema, decompression sickness, or suspected intracranial air. It should also be used with caution in patients with vitamin B12 deficiency, those receiving methotrexate therapy, and patients with severe respiratory disease. Always disclose your complete medical history to the healthcare professional administering the gas.
In most cases, yes. Because nitrous oxide is eliminated from the body very rapidly (within 5 minutes of stopping inhalation), most patients can drive shortly after a procedure. However, if you received additional sedative medications (benzodiazepines, opioids) alongside nitrous oxide, you should not drive for the period specified by your healthcare provider. Always follow the specific advice given to you after your procedure.
References
- European Pharmacopoeia Commission. Nitrous Oxide, Medicinal. European Pharmacopoeia 11th Edition. Strasbourg: EDQM; 2025.
- European Medicines Agency (EMA). Summary of Product Characteristics: Nitrous Oxide Medicinal Gas. EMA Assessment Report. 2023.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List. Geneva: WHO; 2023. Nitrous oxide listed as essential anaesthetic agent.
- Becker DE, Rosenberg M. Nitrous oxide and the inhalation anesthetics. Anesth Prog. 2008;55(4):124-131. doi:10.2344/0003-3006-55.4.124
- Sanders RD, Weimann J, Maze M. Biologic effects of nitrous oxide: a mechanistic and toxicologic review. Anesthesiology. 2008;109(4):707-722. doi:10.1097/ALN.0b013e3181870a17
- Rosen MA. Nitrous oxide for relief of labor pain: a systematic review. Am J Obstet Gynecol. 2002;186(5 Suppl):S110-S126. doi:10.1067/mob.2002.121259
- Myles PS, Leslie K, Chan MT, et al. The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): a randomised, single-blind trial. Lancet. 2014;384(9952):1446-1454. doi:10.1016/S0140-6736(14)60893-X
- Chanarin I. Cobalamins and nitrous oxide: a review. J Clin Pathol. 1980;33(10):909-916. doi:10.1136/jcp.33.10.909
- National Institute for Health and Care Excellence (NICE). Intrapartum care for healthy women and babies. NICE Guideline CG190 (Updated 2023). Section on nitrous oxide for labour pain.
- American Society of Anesthesiologists (ASA). Practice Guidelines for Moderate Procedural Sedation and Analgesia 2018. Anesthesiology. 2018;128(3):437-479.
Medical Editorial Team
This article was written and reviewed by iMedic’s medical editorial team, comprising licensed specialist physicians and pharmacists with expertise in anaesthesiology, clinical pharmacology, and pain management.
iMedic Medical Editorial Team – specialists in anaesthesiology and clinical pharmacology with documented academic backgrounds and clinical experience in procedural sedation, obstetric analgesia, and medical gas therapy.
iMedic Medical Review Board – an independent panel of senior medical specialists who verify all content against current international guidelines (WHO, EMA, ESA, NICE, ASA) and the GRADE evidence framework.
Editorial Standards: All content follows the iMedic Editorial Standards, which require peer-reviewed sources, transparent conflict-of-interest declarations, and regular content updates. This article reflects evidence level 1A based on systematic reviews, randomised controlled trials, and international clinical guidelines.